All In Biotech

Drug Trial Radar · NCT06233461

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

A Phase 2b, Multicenter, Randomized, Double-Blind Induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Crohn's Disease

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 268 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

268

Planned (sponsor's estimate)

Start

Mar 5, 2024

Primary completion

Feb 17, 2027

Study completion Jul 23, 2027

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jan 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate medical problems. An endoscopy will be used to check the bowel for inflammation. The participants will be treated with TAK-279 for 52 weeks (1 year). During the study, participants will visit their study clinic 15 times.

Conditions

  • Crohn's Disease

Interventions

  • TAK-279Drug

    TAK-279 capsules.

  • PlaceboDrug

    TAK-279 placebo-matching capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Endoscopic Response Based on Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 12Time frame: Week 12

Locations

201 sites in 25 countries. Site status is shown where the registry gives one.

  • United Medical Doctors

    Murrieta, California · Recruiting

  • UCI Health

    Orange, California · Recruiting

  • West Central Gastroenterology, LLP, d/b/a/ Gastro Florida

    Clearwater, Florida · Recruiting

  • Auzmer Research

    Lakeland, Florida · Recruiting

  • Wellness Clinical Research

    Miami Lakes, Florida · Recruiting

  • GI PROS, Inc.

    Naples, Florida · Recruiting

  • AdventHealth (Florida Hospital) Medical Group

    Orlando, Florida · Not yet recruiting

  • USF Health Morsani Center for Advanced Healthcare

    Tampa, Florida · Recruiting

  • Emory University Hospital, The Emory Clinic

    Atlanta, Georgia · Recruiting

  • Atlanta Center For Gastroenterology, P.C.

    Decatur, Georgia · Recruiting

  • The University of Iowa Hospitals & Clinics

    Iowa City, Iowa · Recruiting

  • University of Kansas Medical Center

    Kansas City, Kansas · Recruiting

  • University Of Louisville

    Louisville, Kentucky · Recruiting

  • Woodholme Gastroenterology Associates

    Glen Burnie, Maryland · Recruiting

  • BVL Clinical Research

    Liberty, Missouri · Recruiting

  • Las Vegas Medical Research

    Las Vegas, Nevada · Recruiting

  • Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)

    New York, New York · Recruiting

  • Rochester Clinical Research, Inc

    Rochester, New York · Not yet recruiting

  • Great Lakes Gastroenterology Research, LLC

    Mentor, Ohio · Recruiting

  • Hightower Clinical - SSM Health

    Oklahoma City, Oklahoma · Completed

  • University Gastroenterology Providence

    Providence, Rhode Island · Recruiting

  • Gastroenterology Associates, PA

    Greenville, South Carolina · Recruiting

  • Novel Research, LLC

    Bellaire, Texas · Recruiting

  • TDDC - Baylor University Medical Center Gaston Ave

    Dallas, Texas · Completed

  • Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance

    Fort Worth, Texas · Completed

  • One of a Kind Clinical research Center TX LLC

    Kingwood, Texas · Recruiting

  • TDDC dba Alliance Research

    Mansfield, Texas · Completed

  • Southern Star Research Institute, LLC

    San Antonio, Texas · Recruiting

  • Tyler Research Institute, LLC

    Tyler, Texas · Recruiting

  • University of Washington Medical Center

    Seattle, Washington · Recruiting

  • Northern Hospital Epping

    Epping, Australia · Recruiting

  • Sir Charles Gairdner Hospital (SCGH) - Comprehensive Cancer Centre

    Nedlands, Australia · Recruiting

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia · Recruiting

  • Mater Cancer Care Centre-Mater Health Services

    South Brisbane, Queensland, Australia · Recruiting

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia · Recruiting

  • The Queen Elizabeth Hospital

    Woodville, South Australia, Australia · Recruiting

  • Western Health/Footscray Hospital

    Footscray, Victoria, Australia · Recruiting

  • Harry Perkins Medical Research Institute Fiona Stanley Hospital

    Murdoch, Western Australia, Australia · Recruiting

  • Royal Perth Hospital

    Perth, Western Australia, Australia · Recruiting

  • CHU Saint-Pierre - Porte de Hal

    Brussels, Belgium · Recruiting

Showing 40 of 201 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.